Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) by Wolfgang M. Brueckl, Joachim H. Ficker, Gloria Zeitler

Get full text

Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study by Wolfgang M. Brueckl, H. Jost Achenbach, Joachim H. Ficker, Wolfgang Schuette

Get full text

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy by Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H. Ficker, Wolfgang M. Brueckl

Get full text

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report by Markus Falk, Stefanie Schatz, Fabian P. M. Reich, Stefanie Schmidt, Marco Galster, Markus Tiemann, Joachim H. Ficker, Wolfgang M. Brueckl

Get full text

C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study by Jakob M. Riedl, Dominik A. Barth, Wolfgang M. Brueckl, Gloria Zeitler, Vasile Foris, Stefanie Mollnar, Michael Stotz, Christopher H. Rossmann, Angelika Terbuch, Marija Balic, Tobias Niedrist, Thomas Bertsch, Herbert Stoeger, Martin Pichler, Horst Olschewski, Gudrun Absenger, Joachim H. Ficker, Armin Gerger, Florian Posch

Get full text